Fifth Third Bancorp
RPRX icon

Fifth Third Bancorp’s Royalty Pharma RPRX Stock Holding History

Fifth Third Bancorp’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169K Sell
3,013
-141
-4% -$7.34K ﹤0.01% 2701
2026
Q1 		$151K Sell
3,154
-502
-14% -$22K ﹤0.01% 2700
2025
Q4 		$141K Buy
3,656
+1,157
+46% +$44.1K ﹤0.01% 1080
2025
Q3 		$88.2K Buy
2,499
+362
+17% +$13.1K ﹤0.01% 1275
2025
Q2 		$77K Buy
2,137
+344
+19% +$11.4K ﹤0.01% 1248
2025
Q1 		$55.8K Buy
1,793
+263
+17% +$8.34K ﹤0.01% 1351
2024
Q4 		$39K Buy
1,530
+997
+187% +$26.4K ﹤0.01% 1480
2024
Q3 		$15.1K Buy
533
+92
+21% +$2.55K ﹤0.01% 1870
2024
Q2 		$11.6K Sell
441
-23
-5% -$638 ﹤0.01% 1884
2024
Q1 		$14.1K Sell
464
-5,434
-92% -$160K ﹤0.01% 1770
2023
Q4 		$166K Buy
5,898
+170
+3% +$4.67K ﹤0.01% 1017
2023
Q3 		$155K Buy
5,728
+242
+4% +$7.19K ﹤0.01% 1013
2023
Q2 		$169K Sell
5,486
-23
-0.4% -$779 ﹤0.01% 1002
2023
Q1 		$198K Buy
5,509
+52
+1% +$1.93K ﹤0.01% 1017
2022
Q4 		$216K Sell
5,457
-12
-0.2% -$501 ﹤0.01% 921
2022
Q3 		$219K Buy
5,469
+12
+0.2% +$513 ﹤0.01% 920
2022
Q2 		$229K Hold
5,457
– – ﹤0.01% 911
2022
Q1 		$213K Buy
5,457
+1,707
+46% +$67K ﹤0.01% 982
2021
Q4 		$149K Buy
+3,750
New +$146K ﹤0.01% 1107
2021
Q3 		– Sell
-251
Closed -$10K – 2731
2021
Q2 		$10K Buy
+251
New +$10.7K ﹤0.01% 2018
2021
Q1 		– Sell
-2,000
Closed -$100K – 2484
2020
Q4 		$100K Hold
2,000
– – ﹤0.01% 1148
2020
Q3 		$84K Hold
2,000
– – ﹤0.01% 1161
2020
Q2 		$97K Buy
+2,000
New +$99K ﹤0.01% 1107

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fifth Third Bancorp's RPRX Position: Q2 2026 in Review

Fifth Third Bancorp reduced its Royalty Pharma (RPRX) stake by 4.5% in Q2 2026, selling an estimated $7.34K and leaving 3,013 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #2701.

Fifth Third Bancorp first reported a position in RPRX in Q2 2020 and has held it in 23 quarters since. The position peaked at $229K in Q2 2022. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Fifth Third Bancorp held 3,013 shares of Royalty Pharma worth $169K as of Q2 2026.
  • Fifth Third Bancorp sold 141 Royalty Pharma shares in Q2 2026, an estimated $7.34K.
  • Royalty Pharma made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #2701 holding.
  • Fifth Third Bancorp first reported a position in Royalty Pharma in Q2 2020 and has held it in 23 quarters since.
  • Fifth Third Bancorp's Royalty Pharma position peaked at $229K in Q2 2022.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.